This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van Hal, N. L. W. Articles by Brakenhoff, R. H. Search for Related Content PubMed PubMed Citation Articles by Van Hal, N. L. W. Articles by Brakenhoff, R. H.

Evaluation of Soluble CD44v6 as a Potential Serum Marker for Head and Neck Squamous Cell Carcinoma

Department of Otolaryngology/Head and Neck Surgery, University Hospital Vrije Universiteit, 1007 MB Amsterdam, the Netherlands [N. L. W. V. H., G. A. M. S. V. D., C. B. M. T. B., G. B. S., R. H. B.], and Boehringer Ingelheim Research and Development [K-H. H.] and Department of Product Development & Acquisition, Bender MedSystems [I. R-W.], A-1121 Vienna, Austria

In recent years, the measurement of soluble CD44 levels in the circulation of patients with malignant diseases has been introduced as a new and simple diagnostic tool for the detection of human cancer. The high CD44v6 expression in head and neck squamous cell carcinoma (HNSCC) would enable the use of soluble CD44v6 proteins present in the circulation of HNSCC patients as a marker of disease. In the present study, we determined CD44v6 plasma levels using a domain-specific ELISA in healthy volunteers, non-cancer patients, and HNSCC patients before and after surgical removal of the tumor. A difference between the CD44v6 plasma levels of HNSCC patients and controls could not be observed. Moreover, surgical removal of the tumor did not result in a reduction of the CD44v6 plasma level in the HNSCC patients. In addition, the spectrum of soluble v6-containing CD44 proteins present in the plasma of HNSCC patients and controls was determined by immunoprecipitation experiments, but again, tumor-related isoforms could not be distinguished in patient samples.

Additional experiments to unravel the biological source of these circulating proteins indicated surprisingly that the v6-containing proteins present in the circulation of healthy individuals are only released in part, if at all, by activated lymphocytes or other nucleated blood cells. Most circulating CD44v6 proteins seem to be derived from the normal epithelial cell compartments, including breast cells, colon cells, and squamous cells. Taken together, these data do not support the use of soluble CD44v6 as a tumor marker in HNSCC or any other tumor type that has developed from tissues producing soluble isoforms.

This article has been cited by other articles:

				E. J. Franzmann, E. P. Reategui, F. Pedroso, F. G. Pernas, B. M. Karakullukcu, K. L. Carraway, K. Hamilton, R. Singal, and W. J. Goodwin Soluble CD44 Is a Potential Marker for the Early Detection of Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1348 - 1355. [Abstract] [Full Text] [PDF]

				E. J. Franzmann, E. P. Reategui, K. L. Carraway, K. L. Hamilton, D. T. Weed, and W. J. Goodwin Salivary Soluble CD44: A Potential Molecular Marker for Head and Neck Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 735 - 739. [Abstract] [Full Text] [PDF]

				D. A. Scott, J. A. Stapleton, R. M. Palmer, R. F. Wilson, G. Sutherland, P. Y. Coward, G. Gustavsson, E. W. Odell, and R. N. Poston Plasma Concentrations of Reputed Tumor-associated Soluble CD44 Isoforms (v5 and v6) in Smokers Are Dose Related and Decline on Smoking Cessation Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1211 - 1214. [Abstract] [Full Text]